Identification of novel human leukocyte antigen-A*0201-restricted, Cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy Article

Ji, J, Judkowski, VA, Liu, G et al. (2014). Identification of novel human leukocyte antigen-A*0201-restricted, Cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy . 3(3), 356-364. 10.5966/sctm.2013-0135

cited authors

  • Ji, J; Judkowski, VA; Liu, G; Wang, H; Bunying, A; Li, Z; Xu, M; Bender, J; Pinilla, C; Yu, JS

authors

abstract

  • Targeting cancer stem cells (CSCs) with immunotherapy may be an effective means to prevent recurrences in glioblastoma multiforme (GBM). It is well established that CD133 is expressed in the population of GBM tumor cells representing CSCs. This raises a possibility that CD133 could serve as a potential target for cytotoxic T cells (CTLs) to target glioblastoma cancer stem cells. Two potential human leukocyte antigen (HLA)-A*0201-restricted CD133 epitopes, ILSAFSVYV (CD133-405) and YLQWIEFSI (CD133-753), showed strong binding to HLA-A*0201 molecules. In vitro immunogenicity studies generated peptide-specific CD8+ CTLs from normal donors. Autologous monocyte-derived dendritic cells pulsed with the CD133-405 or CD133-753 peptides generated CTLs that efficiently recognized the CD133 epitopes presented in T2 HLA-A*0201 cells and specifically lysed CD133+ HLA-A*0201+ GBM CSCs. These studies demonstrated natural processing and subsequent presentation of these epitopes in GBM CSCs and the ability of CTLs to kill CSCs bearing the antigen. Immunization studies in mice using the mouse homolog CD133 epitopes demonstrated immunogenicity in the absence of autoimmune damage. The results presented in this study support the use of CD133-specific epitope vaccines to target CSCs in glioblastoma and other cancers. © AlphaMed Press 2014.

publication date

  • January 1, 2014

Digital Object Identifier (DOI)

start page

  • 356

end page

  • 364

volume

  • 3

issue

  • 3